Begoña Mellado

Hospital Clínic de Barcelona — Spain

Medicine · Health Sciences

47h-index10.5kcitations361works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(172), Bladder and Urothelial Cancer Treatments(61), Radiopharmaceutical Chemistry and Applications(61), Renal cell carcinoma treatment(60), Cancer Immunotherapy and Biomarkers(42)

Publications356 total

Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025· 1 citedOpen Access
Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
2025Open Access
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Clinical Cancer Research·2025· 7 citedOpen Access
Exercise in patients with metastatic prostate cancer: A comprehensive review
Cancer Treatment Reviews·2025
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression
International Journal of Molecular Sciences·2025· 2 citedOpen Access
Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]
European Urology Open Science·2025Open Access
Safety and pharmacokinetics of mevrometostat (M) in combination with enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025
Ipilimumab/nivolumab versus standard of care in non-clear cell renal cancer: Results of the SUNNIFORECAST trial and potential role of the CPS score and tumor nephrectomy.
Journal of Clinical Oncology·2025
Mevrometostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
Journal of Clinical Oncology·2025
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Journal of Clinical Oncology·2025
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]
European Urology Oncology·2025
Benefits of a mindfulness and compassion program for cancer patients: experience in a Spanish public hospital setting
Clinical & Translational Oncology·2025Open Access
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
Annals of Oncology·2025· 24 citedOpen Access
Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer
Biomedicines·2025· 2 citedOpen Access
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
Breast Cancer Research and Treatment·2025· 5 cited
Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.
Journal of Clinical Oncology·2025
page 1 of 18Next →

Frequent Co-authors

Daniel Castellano(10), Enrique Gallardo(8), Pere Gascón(8), Mercedes Marín‐Aguilera(8), Pedro L. Fernández(7), Jesús García-Donás(6), Ignacio Durán(6), Aranzazu González del Alba(6), Javier Puente(6), Albert Font(6), Jordi Codony‐Servat(6), Andrea Necchi(5), Se Hoon Park(5), Arlene O. Siefker‐Radtke(5), Ugo De Giorgi(5), José Ángel Arranz(5), Joan Carles(5), Joaquim Bellmunt(5), Joan Albanell(5), José Luis Perez‐Gracia(5)